The latest update is out from VGI Partners Asian Investments Ltd ( (AU:RG8) ).
Regal Asian Investments Limited has updated its investors on the impact of negative Phase 3 clinical trial results from Opthea Limited, a biopharmaceutical company in its portfolio. As a result, Regal has revalued its holding in Opthea, affecting its net tangible asset backing, which is now estimated at $2.19 per share. This development highlights the potential volatility in the company’s portfolio due to external factors affecting its investments.
More about VGI Partners Asian Investments Ltd
Regal Asian Investments Limited (ASX:RG8) offers investors access to a concentrated portfolio with long and short positions in securities focused on the Asian region. The company transitioned its portfolio management to Regal Funds Management in 2022, reflecting a strategic shift towards leveraging Regal’s expertise in alternative investments.
YTD Price Performance: -4.33%
Average Trading Volume: 113,070
Technical Sentiment Signal: Sell
Find detailed analytics on RG8 stock on TipRanks’ Stock Analysis page.